Study of inhaled GDC-6988 for mucus lung diseases
Part of Lungs & breathing clinical trials.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lung condition with too much mucus, like chronic bronchitis, bronchiectasis, or COPD
- Your lung function (FEV1) is at least 40% of what's expected for your age and height
- Your condition has been stable for the past 28 days (no sudden flare-ups or infections)
- You are on a stable set of medicines for your lungs for at least 28 days and willing to stay on them
- For some parts of the study: you produce at least a teaspoon of mucus daily and can provide a sputum (mucus) sample
- You are not currently pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study tests a new medicine called galvokimig for adults with non-cystic fibrosis bronchiectasis, a condition where airways are damaged and cause chronic cough and sputum. The goal is to see if it reduces flare-ups and improves lung health.
This trial tests a new drug, BBT002, first in healthy volunteers and then in people with chronic obstructive pulmonary disease (COPD) or chronic sinusitis with nasal polyps. It aims to see if the drug is safe and how it works in the body.
This Phase 2 trial tests 4D-710 to improve lung health in adults with cystic fibrosis who either cannot take CFTR modulator medicines or are not doing well enough on them. You may be eligible if you have moderate lung function and stable oxygen levels, and you meet other safety and health requirements.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.